<DOC>
	<DOCNO>NCT01567397</DOCNO>
	<brief_summary>Experience Microbial Collagenase ( trade name Xiapex ) Europe currently limit randomise control studies.While study essential determine efficacy safety product ( usually compare placebo ) , provide information effectiveness drug aspect use ( feasibility , tolerability , quality life patient-related outcome ) typical `` real-life '' set clinical practice conditions.Thus , present study aim collect data - Drug utilization Microbial Collagenase hand physician , focus feasibility , treatment pattern , effectiveness clinical practice - Context Microbial Collagenase therapy ( set , patient characteristic , concomitant treatment , follow-up therapy ) - Effectiveness ( focus functionality ) - Tolerability - Patient-related outcome : patient satisfaction , health-related quality life - Physician satisfaction therapy - Resource utilization ( hospital stay , drug consumption , concomitant medication etc . ) - Long-term outcome</brief_summary>
	<brief_title>Registry Dupuytren 's Contracture Treatment Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>palpable cord due Dupuytren 's Disease ( pretreated untreated ) satisfactory knowledge German able fill questionnaire write informed consent contraindication Microbial Collagenase ( accord Prescription Information )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>